Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Aug;9(8):1881-3.
doi: 10.3748/wjg.v9.i8.1881.

Single-dose daclizumab induction therapy in patients with liver transplantation

Lu-Nan Yan  1 , Wei Wang, Bo Li, Shi-Chun Lu, Tian-Fu Wen, Qi-Yuan Lin, Yong Zeng, Nan-Sheng Cheng, Ji-Chun Zhao, Yue-Meng Dai
Affiliations

Single-dose daclizumab induction therapy in patients with liver transplantation

Lu-Nan Yan et al. World J Gastroenterol. 2003 Aug.

Abstract

Aim: To investigate the efficacy and safety of a single-dose daclizumab induction therapy in orthotopic liver transplantation (OLTx).

Methods: A retrospective study was made for 54 cases of OLTx in recent three years. The daclizumab group consisted of 23 cases of OLTx who received single-dose of 2 mg/kg intravenously after postoperative 24 hours. The control group consisted of the remaining 31 patients. Additional immunosuppressors included steroids, mycomphenolate mofetil, facrolimus or microemulsion cyclosporine used in all patients. Meta-statistical analysis was made for general data, incidence of acute rejection and infection, postoperative clinical course, complications and prognosis between two groups.

Results: Pretransplant demographies were not significantly different between two groups. In the induction group there were significantly less acute rejection episodes (5 of 23, 21.74 %) than those in the control group (12 of 31, 38.71 %), which were proved by pathologic diagnosis (P<0.05). The incidence of infection at the early stage was not significantly different between two groups.

Conclusion: Induction therapy with single-dose of daclizumab is safe and effective and appears to be able to reduce the incidence of acute rejection.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Eckhoff DE, McGuire B, Sellers M, Contreras J, Frenette L, Young C, Hudson S, Bynon JS. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. Transplantation. 2000;69:1867–1872. - PubMed
    1. Kwekkeboom J, Zondervan PE, Kuijpers MA, Tilanus HW, Metselaar HJ. Fine-needle aspiration cytology in the diagnosis of acute rejection after liver transplantation. Br J Surg. 2003;90:246–247. - PubMed
    1. Ramji A, Yoshida EM, Bain VG, Kneteman NM, Scudamore CH, Ma MM, Steinbrecher UP, Gutfreund KS, Erb SR, Partovi N, et al. Late acute rejection after liver transplantation: the Western Canada experience. Liver Transpl. 2002;8:945–951. - PubMed
    1. Levy GA. Neoral is superior to FK 506 in liver transplantation. Transplant Proc. 1998;30:1812–1815. - PubMed
    1. Niemeyer G, Koch M, Light S, Kuse ER, Nashan B. Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients. Am J Transplant. 2002;2:454–460. - PubMed